Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK525499PMID: 30222291
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1187594-09-7
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of baricitinib during breastfeeding. Most sources recommend that mothers not breastfeed while taking baricitinib. An alternate drug is preferred, especially while nursing a newborn or preterm infant. The manufacturer recommends that women avoid nursing during therapy and for 4 days after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
(Rheumatoid Arthritis) Adalimumab, Certolizumab Pegol, Etanercept, Infliximab, Tocilizumab
Substance Identification
Substance Name
Baricitinib
CAS Registry Number
1187594-09-7
Drug Class
Breast Feeding
Milk, Human
Antirheumatic Agents
Enzyme Inhibitors
Janus Kinase Inhibitors
JAK Inhibitors
Signal Transduction Inhibitors
Protein Kinase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Identification, Synthesis, and Characterization of Novel Baricitinib Impurities.[ACS Omega. 2023]Identification, Synthesis, and Characterization of Novel Baricitinib Impurities.Vaddamanu G, Goswami A, Reddy NRS, Kumar Reddy KRV, Mulakayala N. ACS Omega. 2023 Mar 14; 8(10):9583-9591. Epub 2023 Mar 2.
- Review Upadacitinib.[Drugs and Lactation Database (...]Review Upadacitinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Pemetrexed.[Drugs and Lactation Database (...]Review Pemetrexed.. Drugs and Lactation Database (LactMed®). 2006
- Review Fedratinib.[Drugs and Lactation Database (...]Review Fedratinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Tofacitinib.[Drugs and Lactation Database (...]Review Tofacitinib.. Drugs and Lactation Database (LactMed®). 2006
- Baricitinib - Drugs and Lactation Database (LactMed®)Baricitinib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...